News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Wordsmith AI Raises $70M Series B for In-House Legal Work
Wordsmith AI closed a $70M Series B led by Highland Europe and Index Ventures. The legal AI platform processes routine requests through agents while lawyers approve judgment calls. Over 500 customers already live.
LawGeex Founder Cuts Contract Review to $117, 24 Hours with Utah Law Firm
Noory Bechor has launched Superlegal, an AI-first law firm licensed in Utah that reviews commercial contracts for $117 each in under 24 hours. A construction client reports 90% cost savings versus traditional counsel.
6,200 deals reveal where transaction work really happens
Analysis of 6,200 transactions across law firms shows most deal work occurs weeks before signing, not at closing. Firms organizing around pre-execution structure see faster closings and better client visibility.
Law firm AI costs will triple in 3 years, study estimates
Token costs for frontier models will surge as lawyers move from learner-driver usage to power-user workflows. Law firm CFOs need to budget now for the hidden bill.
Ingenix raises €13M to scale drug-development AI architecture
Biotech startup Ingenix secured €13 million from Sofinnova Partners to expand Modality Fusion, its architecture for accelerating drug discovery. The funding signals investor confidence in fusion-based approaches to computational drug development.
Solidion patents extreme-climate battery for orbit AI data centers
Solidion Technology claims a patented battery design for low Earth orbit operations and lunar infrastructure. The company targets space-based AI compute, but independent performance data is not yet public.
JJP Biologics Halts Dapsone Use in IgA Disease With Anti-CD89 Drug
Nebaprubart showed clinical activity within one week in a phase 1b trial, letting patients stop immunosuppressive therapy. The company plans RA and IgA nephropathy trials in 2026.
CSL Gets EU Approval for Measles Protection Without Vaccination
European Commission authorises Privigen for measles prophylaxis in patients who cannot be vaccinated. The move addresses a sharp rise in European measles cases in 2024–2025.
J&J's SLE Drug Hits Phase 2 Target, Holds Gains to Week 52
Nipocalimab met its primary endpoint at 24 weeks in moderate-to-severe lupus, with sustained disease reduction through week 52. The FcRn blocker showed stronger response in autoantibody-positive patients, who make up roughly 80% of SLE cases.
Lilly's $7B Kelonia bet pays off: in vivo CAR-T hits 100% response in myeloma
Kelonia's KLN-1010 achieved complete or near-complete remission in all evaluable myeloma patients at ASCO 2026, with CAR-T persistence exceeding typical ex vivo therapies. Two other in vivo cell programs also advanced.
US Lawmakers Target $136B in Chinese Biotech Deals with New Bill
Michigan lawmakers propose BINSA to let Congress review and block American pharma investments in China. The move follows $25.7B in recent mega-deals by Pfizer and Bristol Myers Squibb.
Regeneron and CytomX expand cancer therapy deal to $4B
Regeneron and CytomX are combining masking and bispecific antibody technology to develop conditionally activated cancer treatments. Here's what the expanded partnership means for oncology pipelines.